5-amino-1-formylisoquinoline thiosemicarbazone: inhibitor of nucleotidyl transferase enzymes [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 3034621 |
| CHEMBL ID | 1866510 |
| MeSH ID | M0063902 |
| Synonym |
|---|
| hydrazinecarbothioamide, 2-[(5-amino-1-isoquinolinyl)methylene]- |
| mls003107199 , |
| 20335-57-3 |
| 5-amino-1-formylisoquinoline thiosemicarbazone |
| smr001822075 |
| isoquinaldaldehyde, 5-amino-, thiosemicarbazone |
| nsc 205105 |
| hydrazinecarbothioamide, 2-((5-amino-1-isoquinolinyl)methylene)- |
| CHEMBL1866510 |
| DTXSID70942488 |
| 2-[(5-aminoisoquinolin-1-yl)methylidene]hydrazine-1-carboximidothioic acid |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 2.8184 | AID624417 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 50.1187 | AID743255 |
| TDP1 protein | Homo sapiens (human) | Potency | 1.4969 | AID686978; AID686979 |
| 67.9K protein | Vaccinia virus | Potency | 3.9472 | AID720579; AID720580 |
| IDH1 | Homo sapiens (human) | Potency | 2.0596 | AID686970 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 10.0000 | AID588591 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 0.8913 | AID624287 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| integrase, partial | Human immunodeficiency virus 1 | IC50 | 42.5915 | AID1053171; AID1053172 |
| lens epithelium-derived growth factor p75 | Homo sapiens (human) | IC50 | 42.5915 | AID1053171; AID1053172 |
| nuclear receptor coactivator 1 isoform 1 [Homo sapiens] | Homo sapiens (human) | IC50 | 19.5410 | AID602168; AID602235 |
| transactivating tegument protein VP16 [Human herpesvirus 1] | Human alphaherpesvirus 1 (Herpes simplex virus type 1) | IC50 | 2.6570 | AID602167; AID602236 |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | IC50 | 3.4340 | AID602166; AID602234 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| cystic fibrosis transmembrane conductance regulator ATP-binding cassette sub-family C member 7 | Homo sapiens (human) | AC50 | 3.2100 | AID743267 |
| LMP1 [Human herpesvirus 4] | human gammaherpesvirus 4 (Epstein-Barr virus) | AC50 | 53.0075 | AID504861; AID504882 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8 ISSN: 1083-351X |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| edetic acid | ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid | anticoagulant; antidote; chelator; copper chelator; geroprotector | 1977 | 1977 | 47.0 | high | 0 | 1 | 0 | 0 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inflammation | 0 | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | |
| Innate Inflammatory Response | 0 | 2010 | 2010 | 14.0 | high | 0 | 0 | 0 | 1 | 0 | 0 |